Biopharma M&A Resurgence Expected Amid Patent Cliffs, Dwindling Valuations, and Weak IPO Market
Mergers and acquisitions (M&A) have remained relatively languid within the healthcare sector as we moved into the latter half of 2023. However, there is an air of expectancy that this lethargy might be lifted soon. Experts, such as M&A lawyer Matt Gardella from Mintz, argue that market conditions hint towards a resurgence in biopharma M&A…